PELUSO MICHELLE A
Known title: DirectorCIK: 0001271739
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
CVS Health News: Caremark Shift, Settlement Deadline, Defensive Status. CVS Caremark is changing how patients access health services, according to a recent report. The company also faces a settlement claim deadline a month away, with guidance on how to receive the funds. Analysts note that CVS is among a few defensive healthcare stocks being watched as rates remain high, and it has recently outperformed market returns.
Transaction History
| NKE | ▲ Buy | Grant | 5,047 | $0 | 9/8/2026 | View on chart |
| NKE | ▲ Buy | Grant | 2,619 | $0 | 9/9/2025 | View on chart |
| NKE | ▲ Buy | Grant | 2,437 | $0 | 9/10/2024 | View on chart |
| NKE | ▲ Buy | Grant | 1,981 | $0 | 9/12/2023 | View on chart |
| CVS | ▼ Sell | Tax Withholding | 98,299 | $7.3M | 4/1/2023 | View on chart |
| CVS | ▼ Sell | Tax Withholding | 12,304 | $1.1M | 2/27/2023 | View on chart |
| CVS | ▲ Buy | Grant | 192,554 | $0 | 2/2/2023 | View on chart |
| NKE | ▲ Buy | Grant | 1,804 | $0 | 9/9/2022 | View on chart |
| CVS | ▼ Sell | Tax Withholding | 12,609 | $1.3M | 2/26/2022 | View on chart |
| NKE | ▲ Buy | Grant | 1,206 | $0 | 10/6/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Nike shares rise amid value interest and Foot Locker split
Nike stock rose 5% recently as investors focused on its value metrics, despite a lack of major corporate announcements. The company has also ended its partnership with Foot Locker, a move that may impact its retail shelf presence. While only 26% of analysts currently rate the stock a Buy, the average price target remains below the current trading range.
Nike shares rise amid value interest and Foot Locker split. Nike stock rose 5% recently as investors focused on its value metrics, despite a lack of major corporate announcements. The company has also ended its partnership with Foot Locker, a move that may impact its retail shelf presence. While only 26% of analysts currently rate the stock a Buy, the average price target remains below the current trading range.